Monday, 31 August 2026European Markets

KEYWARE TECH. Stock Bullish Momentum With A 11% Rise So Far Today

Loading stream...

(VIANEWS) - Shares of KEYWARE TECH. (BEL 20: KEYW.BR) rose by a staggering 11.8% to €1.00 at 11:22 EST on Thursday, following the last session's upward trend. BEL 20 is falling 0.03% to €3,800.71, following the last session's downward trend. This seems, so far, a somewhat bearish trend trading session today.

KEYWARE TECH.'s last close was €1.03, 10.43% under its 52-week high of €1.15.

About KEYWARE TECH.

Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as engages in the rental and sale of payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 19.9. Meaning, the purchaser of the share is investing €19.9 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.37%.

More news about KEYWARE TECH. (KEYW.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com